Intellia Therapeutics Inc’s filing revealed that its Director Bhanji Muna unloaded Company’s shares for reported $2252.0 on Apr 29 ’25. In the deal valued at $8.50 per share,265 shares were sold. As a result of this transaction, Bhanji Muna now holds 19,203 shares worth roughly $0.17 million.
Then, Clark Eliana sold 679 shares, generating $6,104 in total proceeds. Upon selling the shares at $8.99, the EVP, Chief Technical Officer now owns 95,369 shares.
Before that, BASTA JAMES sold 2,572 shares. Intellia Therapeutics Inc shares valued at $23,122 were divested by the EVP, General Counsel at a price of $8.99 per share. As a result of the transaction, BASTA JAMES now holds 111,925 shares, worth roughly $1.01 million.
Wolfe Research upgraded its Intellia Therapeutics Inc [NTLA] rating to an Outperform from a a Peer perform in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early March with a ‘”a Buy”‘ rating. JP Morgan also remained covering NTLA and has decreased its forecast on February 28, 2025 with a “Neutral” recommendation from previously “an Overweight” rating. Goldman revised its rating on February 28, 2025. It rated NTLA as “a Sell” which previously was an “a Neutral”.
Price Performance Review of NTLA
On Monday, Intellia Therapeutics Inc [NASDAQ:NTLA] saw its stock jump 6.59% to $9.06. Over the last five days, the stock has gained 5.96%. Intellia Therapeutics Inc shares have fallen nearly -22.30% since the year began. Nevertheless, the stocks have fallen -65.45% over the past one year.
How much short interest is there in Intellia Therapeutics Inc?
A steep rise in short interest was recorded in Intellia Therapeutics Inc stocks on 2025-04-30, growing by 1.81 million shares to a total of 28.75 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 26.94 million shares. There was a rise of 6.3%, which implies that there is a positive sentiment for the stock.
